REGENERON PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2018

Regeneron Pharmaceuticals, Inc. (REGN) demonstrated robust financial performance in 2018, with revenues reaching $6.71 billion and net income soaring to $2.44 billion, a significant increase from the previous year. This growth was primarily driven by strong sales of its key products, notably EYLEA, which continues to be the company's primary revenue generator, and increasing contributions from Dupixent and Libtayo. The company's commitment to innovation is evident in its extensive pipeline, with 21 product candidates in clinical development across various therapeutic areas. Collaborations with major pharmaceutical companies like Sanofi and Bayer remain crucial to Regeneron's commercialization strategy, particularly for products like EYLEA outside the U.S. and Dupixent, Praluent, and Kevzara globally. Looking ahead, Regeneron is focused on advancing its pipeline and expanding the indications for its existing products. Key developments in 2018 included positive trial results for Dupixent in adolescent atopic dermatitis and asthma, and for Praluent in cardiovascular risk reduction, with regulatory submissions for these expanded uses underway. The company also received FDA approval for Libtayo for advanced cutaneous squamous cell carcinoma. Investors should monitor the progress of ongoing clinical trials, regulatory decisions, and the impact of competition, especially potential biosimilars for EYLEA, as these factors will significantly influence future financial performance.